Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl^T315I inhibitor overcoming acquired imatinib resistance

References

• Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–3.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619–30.
   PubMed Web of Science ®Google Scholar
• Capdeville R, Buchdunger E, Zimmermann J, et al. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002;1:493–502.
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640–53.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond-exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009;6:535–43.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–17.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Eide CA, Deininger MWN. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007;110:2242–9.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Cowan-Jacob SW, et al. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007;7:345–56.
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129–41.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN 107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia inchronic phase following imatinib resistance and intolerance. Blood 2007;110:3540–6.
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007;109:497–9.
   PubMed Web of Science ®Google Scholar
• Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl + neoplastic cells. Cancer Res 2006;66:11314–22.
   PubMed Web of Science ®Google Scholar
• Modugno M. New resistance mechanisms for small molecule kinase inhibitors of Abl kinase. Drug Discov Today Technol 2014;11:5–10.
   PubMedGoogle Scholar
• Tanaka R, Kimura S. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation. Expert Rev Anticancer Ther 2008;8:1387–98.
   PubMed Web of Science ®Google Scholar
• Noronha G, Cao J, Chow CP, et al. Inhibitors of ABL and the ABL-T315I mutation. Curr Top Med Chem 2008;8:905–21.
   PubMed Web of Science ®Google Scholar
• Schenone S, Brullo C, Botta M. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms. Curr Med Chem 2010;17:1220–45.
   PubMed Web of Science ®Google Scholar
• Lu XY, Cai Q, Ding K. Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation. Curr Med Chem 2011;18:2146–57.
   PubMed Web of Science ®Google Scholar
• Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methyl-piperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010;53:4701–19.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401–12.
   PubMed Web of Science ®Google Scholar
• Choi HG, Ren P, Adrian F, et al. A type-II kinase inhibitor capable of inhibiting the T315I ‘gatekeeper’ mutant of Bcr-Abl. J Med Chem 2010;53:5439–48.
   PubMed Web of Science ®Google Scholar
• Ren XM, Pan XF, Zhang Z, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem 2013;56:879–94.
   PubMed Web of Science ®Google Scholar
• “FDA asks manufacturer of the leukemia drug Iclusig (ponatinib) to suspend marketing and sales”. FDA Drug Safety Communication. U.S. Food and Drug Administration; 2013. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm373040.htm.
   Google Scholar
• Liu X, Kung A, Malinoski B, et al. Development of alkyne-containing pyrazolopyrimidines to overcome drug resistance of Bcr-Abl kinase. J Med Chem 2015;58:9228–37.
   PubMed Web of Science ®Google Scholar
• Lu XY, Zhang Z, Ren XM, et al. Hybrid pyrimidine alkynyls inhibit the clinically resistance related Bcr-Abl(T315I) mutant. Bioorg Med Chem Lett 2015;25:3458–63.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ren XM, Lu XY, et al. GZD856, a novel potent PDGFRα/β inhibitor, suppresses the growth and migration of lung cancer cells in vitro and in vivo. Cancer Lett 2016;375:172–8.
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Veach DR, van der Kuip H, et al. A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood 2005;105:1652–9.
   PubMed Web of Science ®Google Scholar
• Jares-Erijman EA, Jovin TM. FRET imaging. Nat Biotechnol 2003;21:1387–95.
   PubMed Web of Science ®Google Scholar
• Chan WW, Wise SC, Kaufman MD, et al. Conformational control inhibition of the Bcr-abl1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell 2011;19:556–68.
   PubMed Web of Science ®Google Scholar